Abstract
Current data indicate the median survival of patients after lung transplants to be 6.7 years.1 The selection of optimal transplant candidates remains challenging, with many models of patient evaluation currently employed. Indicators of frailty are frequently used to act as prognostic indicators for solid-organ transplant,2,3 with increased frailty having been demonstrated to be associated with prolonged ventilation and length of stay post-transplant.4 Generalized sarcopenia and muscle density have successfully been used as frailty indicators, with Hsu and colleagues5 demonstrating a significant association between psoas muscle sarcopenia and poor outcomes following lung transplantation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Thoracic and Cardiovascular Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
